Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu

CX-5461 OfrRNA Synthesis Inhibitor Cas 1138549-36-6

Price Negotiable
Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable
Product Description

CX-5461 OfrRNA Synthesis Inhibitor Cas 1138549-36-6

 

+ AII PRODUCTS

- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others

 

Product

Size

Price

Stock

Quantity

Get Quotation Now Add to Cart Bulk Inquiry

 

AddThis Sharing Buttons

Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

 

Chemical Information

Product name:CX-5461

Purity:98% min

CAS NO:1138549-36-6

Solubility:DMSO:0.02 mg/mL (0.03 mM)

Molecular Formula:C27H27N7O2S

Package:Packaging according to customer requirements

Molecular Weight:513.61

Storage:Store at -20℃

 

Quality control

Remarks

CX-5461 is an inhibitor ofrRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA withIC50of 142 nM in HCT-116, A375, and MIA PaCa-2 cells, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.

CX-5461 is found to selectively inhibit rRNA synthesis (Pol I IC50=142 nM; Pol II IC50 > 25 M; selectivity ~200-fold) in the HCT-116 cells. Selective inhibition of rRNA synthesis by CX-5461 is confirmed in two other human solid tumor cell lines; melanoma A375 (Pol I IC50 = 113 nM; Pol II IC50 > 25 M) and pancreatic carcinoma MIA PaCa-2 (Pol I IC50=54 nM; Pol II IC50 ~25 mM). CX-5461 possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. CX-5461 exhibits broad antiproliferative potency in a panel of cancer cell lines in human cancer cell lines, but has minimal effect on viability of nontransformed human cells. The median EC50 across all tested cell lines is 147 nM, yet all normal cell lines have EC50 values of approximately 5, 000 nM. Evaluation of the antiproliferative dose response for HCT-116, A375, and MIA PaCa-2 cell lines yield EC50 values of 167, 58, and 74 nM. CX-5461 induces autophagy and senescence in solid tumor cancer cells, rather than apoptosis, through a p53-independent process.

 

Related Prodcuts:

Cisplatin; Gemcitabine HCL; Bleomycin Sulfate; Temozolomide; Carmustine; Fludarabine Phosphate; Nelarabine; Cladribine;Trifluridine; Daptomycin

 

References

[1] Drygin D, et al,

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Taizhou Crene Biotechnology Co., Ltd.
Location Add: Economic Developed Zone of Taizhou Zhejiang China.

Request A Quote

Please check your email address.
Your message must be at least 20 characters.